Clinical trials: Opioid Use
Chronic Low-back Pain
EaseVRx for the Reduction of Chronic Pain and Opioid Use
EaseVRx, a software-based virtual reality (VR) medical device, is intended to offer users a prescription pain management tool that manages the symptoms associated with chronic pain and reduces or eliminates the risk of opioid…
- Trial name
- NCT04139564
- Testing
- EaseVRx headset
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- AppliedVR Inc.
Opioid Withdrawal (Disorder), Opioid Use Disorder
Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.
- Trial name
- NCT07079215
- Testing
- Neurostimulation
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Nu Eyne Co., Ltd.
Opioid Use
Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program
This Clinical Trial will evaluate the Feasibility and Acceptability of Oxygen Saturation Monitoring using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program
- Trial name
- NCT06217380
- Testing
- Masimo SafetyNet Alert (MSNA)
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Dental Anxiety, Dental Pain
Nonpharmacologic Reduction of Periprocedural Distress and Drug Use
Objectives of this Phase I pilot trial are to provide data towards assessing and facilitating feasibility of a larger scale Phase II trial in which the effects of a calmative Comfort Talk® app can be unequivocally evaluated.
- Conditions
- Dental Anxiety, Dental Pain, Drug Use, Opioid Use
- Trial name
- NCT03328208
- Testing
- Comfort Talk® app, White Noise app
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Hypnalgesics, LLC
Opioid Use Disorder
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
The primary purpose of this study was to assess the safety and tolerability of multiple doses of ASP8062 or placebo alone and in combination with a single dose of morphine.
- Trial name
- NCT04448561
- Testing
- ASP8082, morphine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Wisdom Teeth, Wisdom Teeth Extraction or Jaw Implant
NeuroCuple to Mitigate Post-Wisdom Teeth Extraction Opioid Risks
This is a randomized (1:1), placebo-controlled clinical trial that will examine the feasibility and effectiveness of a 2-day application of the NeuroCuple device for pain relief and reduction of opioid use following wisdom teeth…
- Trial name
- NCT07461506
- Testing
- NEUROCUPLE™ Patch
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- nCap Medical
Analgesia
Study of Post-Herniorrhaphy Non-opioid MMA Regimens
This is a Phase 3b, open-label study to assess postoperative opioid use in subjects undergoing unilateral open inguinal herniorrhaphy with intraoperative administration of HTX-011 and a postoperative non-opioid multimodal…
- Trial name
- NCT03907176
- Testing
- HTX-011, Luer lock applicator, Ibuprofen
- Where
- 30 sites in United States
- Volunteers
- 209 people
- Sponsor
- Heron Therapeutics
Opioid-use Disorder
CBT4CBT for Office Based Buprenorphine
In this Phase II SBIR/STTR project, our Specific Aim will be to determine if the use of CBT4CBT-Buprenorphine leads to clinically significant improved outcomes and increased retention for buprenorphine maintenance patients in a…
- Trial name
- NCT03580902
- Testing
- CBT4CBT-Buprenorphine, Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- CBT4CBT, LLC
Opioid-use Disorder, Opioid Withdrawal
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
Clinical performance data for transcutaneous auricular neurostimulation (tAN) as a method to aid in the reduction of symptoms associated with opioid withdrawal in order to support clinical substantial equivalence to a predicate…
- Trial name
- NCT04075214
- Testing
- transcutaneous auricular neurostimulation (tAN)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Spark Biomedical, Inc.
Substance Use Disorders, Opioid Use Disorder
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD)…
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder
- Trial name
- EDITOR (NCT06434818)
- Testing
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Evon Medics LLC
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals
Opioid Use Disorder
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases…
- Trial name
- NCT02672111
- Testing
- CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 228 people
- Sponsor
- Braeburn Pharmaceuticals
Opioid-use Disorder, Depression, Anxiety
Transcranial Photobiomodulation for the Treatment of Opioid Cravings
The investigators wish to test the hypothesis that transcranial photobiomodulation (tPBM) (i.e., 4-minutes of 810nm near-infrared light at 250 mW/cm2 by LED to the forehead at F3 or F4 versus an indistinguishable placebo…
- Conditions
- Opioid-use Disorder, Depression, Anxiety, Craving
- Trial name
- NCT04417738
- Testing
- unilateral transcranial photobiomodulation, near infrared mode
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MindLight, LLC
Pain, Pediatric Cancer
An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients
In this SBIR, ALTality, Inc. ("SpellBound") will assess the feasibility of a dual English/Spanish language augmented reality(AR)-enabled tool for assessing inpatient postoperative pain/nausea/vomiting in Hispanic/Latino children…
- Trial name
- NCT06635434
- Testing
- AR Pain assessment
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ALTality, Inc.
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Chronic Pain, Opioid Use
Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain
The purpose of this study is to develop and test the feasibility of a commercially-ready mobile neurofeedback app for individuals with chronic pain.
- Trial name
- NCT04838925
- Testing
- Mobile Neurofeedback App
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CrossComm, Inc.